药物设计的进步和选择性或多目标5-HT1A受体配体的治疗潜力
Gianfabio Giorgioni1, Alessandro Bonifazi2, Luca Botticelli3
1Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
药物化学家正在开发用于神经精神疾病的新型5-HT1A受体配体. 本综述涵盖了选择性,偏向性和多目标化合物,以及成像工具,从2017-2023.
科学领域:
- 药用化学 医学化学
- 神经药理学神经药理学
- 药物发现 药物发现 药物发现
背景情况:
- 5-HT1A受体 (5-HT1A-R) 是一个关键的G蛋白结合受体,参与中枢神经系统和外周功能.
- 它仍然是药物发现的重要目标,因为它在神经精神疾病中的作用.
研究的目的:
- 从2017年到2023年,审查5-HT1A-R配体的药物化学进展.
- 专注于针对复杂疾病的选择性,偏向性和多目标化合物.
- 包括开发用于分子成像的5-HT1A-R工具.
主要方法:
- 结构与活动关系 (SAR) 研究.
- 新联体的设计和合成.
- 对激动剂和抗剂进行药理学分析.
主要成果:
- 在开发选择性/偏好的5-HT1A-R配体方面取得了进展.
- 识别具有不同信号配置的偏向激动剂.
- 对复杂的精神病和神经退行性疾病的多目标化合物的进展.
- 开发用于5-HT1A-R分子成像的化学和药理工具.
结论:
- 5-HT1A-R仍然是一个具有显著治疗潜力的关键目标.
- 药用化学的努力正在为各种应用产生各种各样的配体.
- 多目标策略和成像工具对未来的治疗有很大的前景.
更多相关视频
08:49Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
11:27The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
Published on: April 25, 2012
相关概念视频
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Antidepressant Drugs: MAOIs and Other Agents
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Antipsychotic Drugs: Typical and Atypical Agents
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
